Hauptinhalt

Publikationen Strecker

Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis. Mellors, J., Tipton, T., Fehling, S.K., Akoi Bore, J., Koundouno, F.R., Hall, Y., Hudson, J., Alexander, F., Longet, S., Taylor, S., Gorringe, A., Magassouba, N.F., Konde, M.K., Hiscox, J., Strecker, T., Carroll, M. Frontiers in Immunology. 2022 April 12 (13).

Proteomic landscape of SARS-CoV-2- and MERS-CoV-infected primary human renal epithelial cells. Kohli A, Sauerhering L, Fehling SK, Klann K, Geiger H, Becker S, Koch B, Baer PC, Strecker T, Münch C. Life Sci Alliance. 2022 Feb 2;5(5):e202201371.

CP100356 Hydrochloride, a P-Glycoprotein Inhibitor, Inhibits Lassa Virus Entry: Implication of a Candidate Pan-Mammarenavirus Entry Inhibitor. Takenaga T, Zhang Z, Muramoto Y, Fehling SK, Hirabayashi A, Takamatsu Y, Kajikawa J, Miyamoto S, Nakano M, Urata S, Groseth A, Strecker T, Noda T. Viruses. 2021 Sep 3;13(9):1763.

Polymer microarrays rapidly identify competitive adsorbents of virus-like particles. Blok AJ, Gurnani P, Xenopoulos A, Burroughs L, Duncan J, Urbanowicz RA, Tsoleridis T, Müller-Kräuter H, Strecker T, Ball JK, Alexander C, Alexander MR. Biointerphases. 2020 Nov 17;15(6):061005. doi: 10.1116/6.0000586.

Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study. Thom R, Tipton T, Strecker T, Hall Y, Akoi Bore J, Maes P, Raymond Koundouno F, Fehling SK, Krähling V, Steeds K, Varghese A, Bailey G, Matheson M, Coné M, Moussa Keita B, Kouyate S, Richard Ablam A, Laenen L, Vergote V, Guiver M, Timothy J, Atkinson B, Ottowell L, Richards KS, Bosworth A, Longet S, Mellors J, Pannetier D, Duraffour S, Muñoz-Fontela C, Sow O, Koivogui L, Newman E, Becker S, Sprecher A, Raoul H, Hiscox J, Henao-Restrepo AM, Sakoba K, Magassouba N, Günther S, Kader Konde M, Carroll MW. Lancet Infect Dis. 2020 Oct 13:S1473-3099(20)30736-2. doi: 10.1016/S1473-3099(20)30736-2.

Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies. Steeds K, Hall Y, Slack GS, Longet S, Strecker T, Fehling SK, Wright E, Bore JA, Koundouno FR, Konde MK, Hewson R, Hiscox JA, Pollakis G, Carroll MW. Sci Rep. 2020 Aug 31;10(1):14289. doi: 10.1038/s41598-020-71225-1.

Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. Müller H, Fehling SK, Dorna J, Urbanowicz RA, Oestereich L, Krebs Y, Kolesnikova L, Schauflinger M, Krähling V, Magassouba N, Fichet-Calvet E, Ball JK, Kaufmann A, Bauer S, Becker S, von Messling V, Strecker T. NPJ Vaccines. 2020 Aug 4;5:71. doi: 10.1038/s41541-020-00219-x. eCollection 2020.

Distinct Molecular Mechanisms of Host Immune Response Modulation by Arenavirus NP and Z Proteins. Stott RJ, Strecker T, Foster TL. Viruses. 2020 Jul 21;12(7):784. doi: 10.3390/v12070784.

Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea. Boum Y, Juan-Giner A, Hitchings M, Soumah A, Strecker T, Sadjo M, Cuthbertson H, Hayes P, Tchaton M, Jemmy JP, Clarck C, King D, Faga EM, Becker S, Halis B, Gunnstein N, Carroll M, Røttingen JA, Kondé MK, Doumbia M, Henao-Restrepo AM, Kieny MP, Cisse M, Draguez B, Grais RF. Vaccine. 2020 Jun 1:S0264-410X(20)30583-1. doi: 10.1016/j.vaccine.2020.04.066.

Ebola Virus Neutralizing Antibodies in Dogs from Sierra Leone, 2017. Fischer K, Suluku R, Fehling SK, Jabaty J, Koroma B, Strecker T, Groschup MH, Diederich S. Emerg Infect Dis. 2020 Apr;26(4):760-763. doi: 10.3201/eid2604.190802.

Determining Ancestry between Rodent- and Human-Derived Virus Sequences in Endemic Foci: Towards a More Integral Molecular Epidemiology of Lassa Fever within West Africa. Olayemi A, Adesina AS, Strecker T, Magassouba N, Fichet-Calvet E. Biology (Basel). 2020 Feb 7;9(2). pii: E26. doi: 10.3390/biology9020026.

Post-exposure prophylaxis with rVSV-ZEBOV following exposure to a patient with Ebola virus disease relapse in the UK: an operational, safety and immunogenicity report. Davis C, Tipton T, Sabir S, Aitken C, Bennett S, Becker S, Evans T, Fehling SK, Gunson R, Hall Y, Jackson C, Johanssen I, Kieny MP, McMenamin J, Spence E, Strecker T, Sykes C, Templeton K, Thorburn F, Peters E, Henao Restrepo AM, White B, Zambon M, Carroll MW, Thomson EC. Clin Infect Dis. 2019 Nov 30. pii: ciz1165. doi: 10.1093/cid/ciz1165.

Serological Evidence of Exposure to Ebolaviruses in Domestic Pigs from Guinea. Fischer K, Camara A, Troupin C, Fehling SK, Strecker T, Groschup MH, Tordo N, Diederich S. Transbound Emerg Dis. 2019 Oct 18. doi: 10.1111/tbed.13391.

A Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein (EBOV GP) Nanoparticle Vaccine with Matrix-M™ Adjuvant in Healthy Adults. Fries L, Cho I, Krähling V, Fehling SK, Strecker T, Becker S, Hooper JW, Kwilas SA, Agrawal S, Wen J, Lewis M, Fix A, Thomas N, Flyer D, Smith G, Glenn G. J Infect Dis. 2019 Oct 11. pii: jiz518. doi: 10.1093/infdis/jiz518.

Early transmission and case fatality of Ebola virus at the index site of the 2013-16 west African Ebola outbreak: a cross-sectional seroprevalence survey. Timothy JWS, Hall Y, Akoi-Boré J, Diallo B, Tipton TRW, Bower H, Strecker T, Glynn JR, Carroll MW. Lancet Infect Dis. 2019 Feb 21. pii: S1473-3099(18)30791-6. doi: 10.1016/S1473-3099(18)30791-6. 

Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans. Poetsch JH, Dahlke C, Zinser ME, Kasonta R, Lunemann S, Rechtien A, Ly ML, Stubbe HC, Krähling V, Biedenkopf N, Eickmann M, Fehling SK, Olearo F, Strecker T, Sharma P, Lang KS, Lohse AW, Schmiedel S, Becker S; VSV-Ebola Consortium (VEBCON) , Addo MM. J Infect Dis. 2018 Nov 17. doi: 10.1093/infdis/jiy565.

Serological Evidence for the Circulation of Ebolaviruses in Pigs from Sierra Leone. Fischer K, Jabaty J, Suluku R, Strecker T, Groseth A, Fehling SK, Balkema-Buschmann A, Koroma B, Schmidt KM, Atherstone C, Weingartl HM, Mettenleiter TC, Groschup MH, Hoenen T, Diederich S. J Infect Dis. 2018 Jul 5. doi: 10.1093/infdis/jiy330.

Structure of the Lassa virus glycan shield provides a model for immunological resistance. Watanabe Y, Raghwani J, Allen JD, Seabright GE, Li S, Moser F, Huiskonen JT, Strecker T, Bowden TA, Crispin M. Proc Natl Acad Sci U S A. 2018 Jun 25. pii: 201803990.

Determining the effect of different environmental conditions on Ebola virus viability in clinically relevant specimens. Palyi B, Magyar N, Henczko J, Szalai B, Farkas A, Strecker T, Takacs M, Kis Z.Emerg Microbes Infect. 2018 Mar 29;7(1):52. doi: 10.1038/s41426-018-0043-z.

New Lineage of Lassa Virus, Togo, 2016. Whitmer SLM, Strecker T, Cadar D, Dienes HP, Faber K, Patel K, Brown SM, Davis WG, Klena JD, Rollin PE, Schmidt-Chanasit J, Fichet-Calvet E, Noack B, Emmerich P, Rieger T, Wolff S, Fehling SK, Eickmann M, Mengel JP, Schultze T, Hain T, Ampofo W, Bonney K, Aryeequaye JND, Ribner B, Varkey JB, Mehta AK, Lyon GM 3rd, Kann G, De Leuw P, Schuettfort G, Stephan C, Wieland U, Fries JWU, Kochanek M, Kraft CS, Wolf T, Nichol ST, Becker S, Ströher U, Günther S. Emerg Infect Dis. 2018 Mar;24(3):599-602.

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial. Agnandji ST, Fernandes JF, Bache EB, Obiang Mba RM, Brosnahan JS, Kabwende L, Pitzinger P, Staarink P, Massinga-Loembe M, Krähling V, Biedenkopf N, Fehling SK, Strecker T, Clark DJ, Staines HM, Hooper JW, Silvera P, Moorthy V, Kieny MP, Adegnika AA, Grobusch MP, Becker S, Ramharter M, Mordmüller B, Lell B; VEBCON Consortium, Krishna S, Kremsner PG. PLoS Med. 2017 Oct 6;14(10):e1002402.

Variability of interferon-λ induction and antiviral activity in Nipah virus infected differentiated human bronchial epithelial cells of two human donors. Sauerhering L, Müller H, Behner L, Elvert M, Fehling SK, Strecker T, Maisner A. J Gen Virol. 2017 Oct;98(10):2447-2453.

IRF9 prevents CD8+ T cell exhaustion in an extrinsic manner during acute LCMV infection. Huber M, Suprunenko T, Ashhurst T, Marbach F, Raifer H, Wolff S, Strecker T, Viengkhou B, Jung SR, Obermann HL, Bauer S, Xu HC, Lang P, Tom A, Lang KS, King NJC, Campbell IL, Hofer MJ. J Virol. 2017 Sep 6. pii: JVI.01219-17.

Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. Raabe VN, Kann G, Ribner BS, Morales A, Varkey JB, Mehta AK, Lyon GM, Vanairsdale S, Faber K, Becker S, Eickmann M, Strecker T, Brown S, Patel K, De Leuw P, Schuettfort G, Stephan C, Rabenau H, Klena JD, Rollin PE, McElroy A, Ströher U, Nichol S, Kraft CS, Wolf T; Emory Serious Communicable Diseases Unit. Clin Infect Dis. 2017 Sep 1;65(5):855-859.

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. Dahlke C, Kasonta R, Lunemann S, Krähling V, Zinser ME, Biedenkopf N, Fehling SK, Ly ML, Rechtien A, Stubbe HC, Olearo F, Borregaard S, Jambrecina A, Stahl F, Strecker T, Eickmann M, Lütgehetmann M, Spohn M, Schmiedel S, Lohse AW, Becker S, Addo MM; VEBCON Consortium. EBioMedicine. 2017 May;19:107-118.

 Comprehensive characterization of cellular immune responses following Ebola virus infection. Dahlke C, Lunemann S, Kasonta R, Kreuels B, Schmiedel S, Ly ML, Fehling SK, Strecker T, Becker S, Altfeld M, Sow A, Lohse AW, Muñoz-Fontela C, Addo MM.  J Infect Dis. 2017 Jan 15;215(2):287-292.

Persistence of Ebola virus in the semen of male survivors  Hartmann RK, Grünweller A, Strecker T.  Journal of Public Health and Emergency 2017 Jan 17.

Genome Sequence of Lassa Virus Isolated from the First Domestically Acquired Case in Germany. Wolff S, Schultze T, Fehling SK, Mengel JP, Kann G, Wolf T, Eickmann M, Becker S, Hain T, Strecker T.Genome Announc. 2016 Sep 22;4(5).

Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015. Kerber R, Krumkamp R, Diallo B, Jaeger A, Rudolf M, Lanini S, Bore JA, Koundouno FR, Becker-Ziaja B, Fleischmann E, Stoecker K, Meschi S, Mély S, Newman EN, Carletti F, Portmann J, Korva M, Wolff S, Molkenthin P, Kis Z, Kelterbaum A, Bocquin A, Strecker T, Fizet A, Castilletti C, Schudt G, Ottowell L, Kurth A, Atkinson B, Badusche M, Cannas A, Pallasch E, Bosworth A, Yue C, Pályi B, Ellerbrok H, Kohl C, Oestereich L, Logue CH, Lüdtke A, Richter M, Ngabo D, Borremans B, Becker D, Gryseels S, Abdellati S, Vermoesen T, Kuisma E, Kraus A, Liedigk B, Maes P, Thom R, Duraffour S, Diederich S, Hinzmann J, Afrough B, Repits J, Mertens M, Vitoriano I, Bah A, Sachse A, Boettcher JP, Wurr S, Bockholt S, Nitsche A, Županc TA, Strasser M, Ippolito G, Becker S, Raoul H, Carroll MW, De Clerck H, Van Herp M, Sprecher A, Koivogui L, Magassouba N, Keïta S, Drury P, Gurry C, Formenty P, May J, Gabriel M, Wölfel R, Günther S, Di Caro A. J Infect Dis. 2016 Oct 15;214(suppl 3):S250-S257.

Unique human immune signature of Ebola virus disease in Guinea. Ruibal P, Oestereich L, Lüdtke A, Becker-Ziaja B, Wozniak DM, Kerber R, Korva M, Cabeza-Cabrerizo M, Bore JA, Koundouno FR, Duraffour S, Weller R, Thorenz A, Cimini E, Viola D, Agrati C, Repits J, Afrough B, Cowley LA, Ngabo D, Hinzmann J, Mertens M, Vitoriano I, Logue CH, Boettcher JP, Pallasch E, Sachse A, Bah A, Nitzsche K, Kuisma E, Michel J, Holm T, Zekeng EG, García-Dorival I, Wölfel R, Stoecker K, Fleischmann E, Strecker T, Di Caro A, Avšič-Županc T, Kurth A, Meschi S, Mély S, Newman E, Bocquin A, Kis Z, Kelterbaum A, Molkenthin P, Carletti F, Portmann J, Wolff S, Castilletti C, Schudt G, Fizet A, Ottowell LJ, Herker E, Jacobs T, Kretschmer B, Severi E, Ouedraogo N, Lago M, Negredo A, Franco L, Anda P, Schmiedel S, Kreuels B, Wichmann D, Addo MM, Lohse AW, De Clerck H, Nanclares C, Jonckheere S, Van Herp M, Sprecher A, Xiaojiang G, Carrington M, Miranda O, Castro CM, Gabriel M, Drury P, Formenty P, Diallo B, Koivogui L, Magassouba N, Carroll MW, Günther S, Muñoz-Fontela C. Nature. 2016 May 5;533(7601):100-4.

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA. N Engl J Med. 2016 Apr 28;374(17):1647-1660.

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV. N Engl J Med. 2016 Apr 28;374(17):1635-1646.

The New World Arenavirus Tacaribe induces caspase-dependent apoptosis in infected cells. Wolff S, Groseth A, Meyer B, Jackson D,Strecker T, Kaufmann A, Becker S. J Gen Virol. 2016 Apr;97(4):855-66.

Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. Dowall SD, Callan J, Zeltina A, Al-Abdulla I, Strecker T, Fehling SK, Krähling V, Bosworth A, Rayner E, Taylor I, Charlton S, Landon J, Cameron I, Hewson R, Nasidi A, Bowden TA, Carroll MW. J Infect Dis. 2016 Apr 1;213(7):1124-33.

Spatial and temporal evolution of Lassa virus in the natural host population in Upper Guinea. Fichet-Calvet E, Ölschläger S, Strecker T, Koivogui L, Becker-Ziaja B, Camara AB, Soropogui B, Magassouba N, Günther S. Sci Rep. 2016 Feb 25;6:21977.

Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike. Li S, Sun Z, Pryce R, Parsy ML, Fehling SK, Schlie K, Siebert CA, Garten W, Bowden TA, Strecker T, Huiskonen JT. PLoS Pathog. 2016 Feb 5;12(2):e1005418.

Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies. Geisen C, Kann G, Strecker T, Wolf T, Schüttfort G, van Kraaij M, MacLennan S, Rummler S, Weinigel C, Eickmann M, Fehling SK, Krähling V, Seidl C, Seifried E, Schmidt M, Schäfer R. Vox Sang. 2016 May;110(4):329-35.

Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease. Gignoux E, Azman AS, de Smet M, Azuma P, Massaquoi M, Job D, Tiffany A, Petrucci R, Sterk E, Potet J, Suzuki M, Kurth A, Cannas A, Bocquin A, Strecker T, Logue C, Pottage T, Yue C, Cabrol JC, Serafini M, Ciglenecki I. N Engl J Med. 2016 Jan 7;374(1):23-32.

Field Evaluation of Capillary Blood Samples as a Collection Specimen for the Rapid Diagnosis of Ebola Virus Infection during an Outbreak Emergency. Strecker T, Palyi B, Ellerbrok H, Jonckheere S, de Clerck H, Bore JA, Gabriel M, Stoecker K, Eickmann M, van Herp M, Formenty P, Di Caro A, Becker S. Clin Infect Dis. 2015 Sep 1;61(5):669-75.

Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa. Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G, Rambaut A, Hewson R, García-Dorival I, Bore JA, Koundouno R, Abdellati S, Afrough B, Aiyepada J, Akhilomen P, Asogun D, Atkinson B, Badusche M, Bah A, Bate S, Baumann J, Becker D, Becker-Ziaja B, Bocquin A, Borremans B, Bosworth A, Boettcher JP, Cannas A, Carletti F, Castilletti C, Clark S, Colavita F, Diederich S, Donatus A, Duraffour S, Ehichioya D, Ellerbrok H, Fernandez-Garcia MD, Fizet A, Fleischmann E, Gryseels S, Hermelink A, Hinzmann J, Hopf-Guevara U, Ighodalo Y, Jameson L, Kelterbaum A, Kis Z, Kloth S, Kohl C, Korva M, Kraus A, Kuisma E, Kurth A, Liedigk B, Logue CH, Lüdtke A, Maes P, McCowen J, Mély S, Mertens M, Meschi S, Meyer B, Michel J, Molkenthin P, Muñoz-Fontela C, Muth D, Newman EN, Ngabo D, Oestereich L, Okosun J, Olokor T, Omiunu R, Omomoh E, Pallasch E, Pályi B, Portmann J, Pottage T, Pratt C, Priesnitz S, Quartu S, Rappe J, Repits J, Richter M, Rudolf M, Sachse A, Schmidt KM, Schudt G, Strecker T, Thom R, Thomas S, Tobin E, Tolley H, Trautner J, Vermoesen T, Vitoriano I, Wagner M, Wolff S, Yue C, Capobianchi MR, Kretschmer B, Hall Y, Kenny JG, Rickett NY, Dudas G, Coltart CE, Kerber R, Steer D, Wright C, Senyah F, Keita S, Drury P, Diallo B, de Clerck H, Van Herp M, Sprecher A, Traore A, Diakite M, Konde MK, Koivogui L, Magassouba N, Avšič-Županc T, Nitsche A, Strasser M, Ippolito G, Becker S, Stoecker K, Gabriel M, Raoul H, Di Caro A, Wölfel R, Formenty P, Günther S. Nature. 2015 Aug 6;524(7563):97-101.

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe - Preliminary Report. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA. N Engl J Med. 2015 Apr 1. [Epub ahead of print]

Ebola – Umgang mit der persönlichen Schutzausrüstung (PSA) Bösl E, Dersch W, Fehling SK, Strecker T, Eickmann M, Diederich U, Otto A, Streubel K und Becker S. Intensiv- und Notfallbehandlung, Jahrgang 39, Nr. 4/2014, S. 146–166.

Evidence for a decrease in transmission of Ebola virus--Lofa County, Liberia, June 8-November 1, 2014. Sharma A, Heijenberg N, Peter C, Bolongei J, Reeder B, Alpha T, Sterk E, Robert H, Kurth A, Cannas A, Bocquin A, Strecker T, Logue C, Di Caro A, Pottage T, Yue C, Stoecker K, Wölfel R, Gabriel M, Günther S, Damon I; Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2014 Nov 21;63(46):1067-71.

Interaction with Tsg101 is necessary for the efficient transport and release of nucleocapsids in marburg virus-infected cells. Dolnik O, Kolesnikova L, Welsch S, Strecker T, Schudt G, Becker S. PLoS Pathog. 2014 Oct 16;10(10):e1004463.

Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Dormitzer PR, Suphaphiphat P, Gibson DG, Wentworth DE, Stockwell TB, Algire MA, Alperovich N, Barro M, Brown DM, Craig S, Dattilo BM, Denisova EA, De Souza I, Eickmann M, Dugan VG, Ferrari A, Gomila RC, Han L, Judge C, Mane S, Matrosovich M, Merryman C, Palladino G, Palmer GA, Spencer T, Strecker T, Trusheim H, Uhlendorff J, Wen Y, Yee AC, Zaveri J, Zhou B, Becker S, Donabedian A, Mason PW, Glass JI, Rappuoli R, Venter JC. Sci Transl Med. 2013 May 15;5(185):185ra68.

The microtubule motor protein KIF13A is involved in intracellular trafficking of the Lassa virus matrix protein Z. Fehling SK, Noda T, Maisner A, Lamp B, Conzelmann KK, Kawaoka Y, Klenk HD, Garten W, Strecker T. Cell Microbiol. 2013 Feb;15(2):315-34.

Multifunctional nature of the arenavirus RING finger protein Z. Fehling SK, Lennartz F, Strecker T. Viruses. 2012 Nov 9;4(11):2973-3011.

Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogens. Strecker T, Uhlendorff J, Diederich S, Lenz-Bauer C, Trusheim H, Roth B, Kolesnikova L, Aepinus C, Dornow R, Gerlach J, Matrosovich M, Valley U, Eickmann M, Becker S. Clin Chem Lab Med. 2012 May 23;50(7):1275-9.

Sangassou virus, the first hantavirus isolate from Africa, displays genetic and functional properties distinct from those of other murinae-associated hantaviruses. Klempa B, Witkowski PT, Popugaeva E, Auste B, Koivogui L, Fichet-Calvet E, Strecker T, Ter Meulen J, Krüger DH. J Virol. 2012 Apr;86(7):3819-27.

Maturation cleavage within the ectodomain of Lassa virus glycoprotein relies on stabilization by the cytoplasmic tail. Schlie K, Strecker T, Garten W. FEBS Lett. 2010 Nov 5;584(21):4379-82.

Efficient budding of the tacaribe virus matrix protein z requires the nucleoprotein. Groseth A, Wolff S, Strecker T, Hoenen T, Becker S. J Virol. 2010 Apr;84(7):3603-11.

Viral protein determinants of Lassa virus entry and release from polarized epithelial cells. Schlie K, Maisa A, Freiberg F, Groseth A, Strecker T, Garten W. J Virol. 2010 Apr;84(7):3178-88.

Characterization of Lassa virus glycoprotein oligomerization and influence of cholesterol on virus replication. Schlie K, Maisa A, Lennartz F, Ströher U, Garten W, Strecker T. J Virol. 2010 Jan;84(2):983-92.

Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants. Maisa A, Ströher U, Klenk HD, Garten W, Strecker T. PLoS Negl Trop Dis. 2009 Jun 2;3(6):e446.

Vacuolar protein sorting pathway contributes to the release of Marburg virus. Kolesnikova L, Strecker T, Morita E, Zielecki F, Mittler E, Crump C, Becker S. J Virol. 2009 Mar;83(5):2327-37.

Role of the transmembrane domain of marburg virus surface protein GP in assembly of the viral envelope. Mittler E, Kolesnikova L, Strecker T, Garten W, Becker S. J Virol. 2007 Apr;81(8):3942-8.

The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. Strecker T, Maisa A, Daffis S, Eichler R, Lenz O, Garten W. Virol J. 2006 Nov 5;3:93.

The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C. Eichler R, Lenz O, Garten W, Strecker T. Virol J. 2006 May 31;3:41.

Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Meulen Jt, Badusche M, Satoguina J, Strecker T, Lenz O, Loeliger C, Sakho M, Koulemou K, Koivogui L, Hoerauf A. Virology. 2004 Mar 30;321(1):134-43.

Lassa virus glycoprotein signal peptide displays a novel topology with an extended endoplasmic reticulum luminal region. Eichler R, Lenz O, Strecker T, Eickmann M, Klenk HD, Garten W. J Biol Chem. 2004 Mar 26;279(13):12293-9.

Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP). Eichler R, Strecker T, Kolesnikova L, ter Meulen J, Weissenhorn W, Becker S, Klenk HD, Garten W, Lenz O. Virus Res. 2004 Mar 15;100(2):249-55.

Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. Eichler R, Lenz O, Strecker T, Eickmann M, Klenk HD, Garten W. EMBO Rep. 2003 Nov;4(11):1084-8.

Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles. Strecker T, Eichler R, Meulen Jt, Weissenhorn W, Dieter Klenk H, Garten W, Lenz O. J Virol. 2003 Oct;77(19):10700-5.

Signal peptide of Lassa virus glycoprotein GP-C exhibits an unusual length. Eichler R, Lenz O, Strecker T, Garten W. FEBS Lett. 2003 Mar 13;538(1-3):203-6.